A practical reference on somatotroph: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Initially, PKCε was thought to protect mitochondria from MPT through its association with VDAC1, ANT, and hexokinase II; however, genetic studies have since ruled this out and subsequent studies have identified the F0/F1 ATP synthase as a core inner mitochondrial membrane component and Bax and Bak as potential outer membrane components These findings have opened up new avenues of investigation for the role of PKCε at mitochondria. Several likely targets of PKCε action affecting MPT have been discovered. PKCε interacts with ERK, JNKs and p38, and PKCε directly or indirectly phosphorylates ERK and subsequently Bad. PKCε also interacts with Bax in cancer cells, and PKCε modulates its dimerization and function. Activation of PKCε with the specific activator, εRACK, prior to ischemic injury has shown to be associated with phosphorylation of the F0/F1 ATP synthase. Moreover, the modulatory component, ANT is regulated by PKCε. These data suggest that PKCε may act at multiple modulatory targets of MPT function; further studies are required to unveil the specific mechanism.
==== Post-traumatic growth in constructive journalism ==== The phenomenon of PTG is applicable to many disciplines. The construct is important not only for just soldiers, emergency responders, and survivors of traumatic events, but on average, for everyday citizens facing typical adversity. One way to expose citizens to stories of PTG is through constructive journalism. Constructive journalism, as defined by PhD student Karen McIntyre at University of North Carolina Chapel Hill, is "an emerging style of journalism in which positive psychology techniques are applied to news work with the aim of engaging readers by creating more productive news stories, all while maintaining core journalistic functions". Cathrine Gyldensted, an experienced reporter with a Masters in applied positive psychology and coauthor of two books, demonstrated that typical news reporting, which is associated with negative valence, harms mood. Using PTG to focus on victims' strengths and instances of overcoming adversity encourages readers to implement similar ideals in their own lives. "So the goal of positive psychology in well-being theory is to measure and to build human flourishing." Combining positive psychology constructs like PTG, PERMA, and "broaden and build" with journalism could potentially improve affect and inspire individuals about the benefits of positive psychology. PERMA not only plays a role in our own personal lives but also can be used for public major news stories.
Solid phase microextraction, or SPME, is a solid-phase extraction sampling technique that involves the use of a fiber coated with an extracting phase, that can be a liquid (polymer) or a solid (sorbent), which extracts different kinds of analytes (including both volatile and non-volatile) from different kinds of media, that can be in liquid or gas phase. The quantity of analyte extracted by the fibre is proportional to its concentration in the sample as long as equilibrium is reached or, in case of short time pre-equilibrium, with help of convection or agitation.
==== Anticoagulants ==== Anticoagulants are considered more aggressive than antiplatelet drugs. Anticoagulants work by interfering with various clotting factors to lengthen the time for coagulation. This can be achieved by either reducing the formation of bioactive clotting factors or accelerating the inactivation of clotting factors.
The new 33rd district, previously encompassing mostly Hispanic parts of the Dallas–Fort Worth metroplex including Downtown Fort Worth, western Dallas, and parts of Grand Prairie, Irving, Carrollton, and Farmers Branch, has since been redrawn to be exclusively within Dallas County. Prior to redistricting, the incumbent was Fort Worth-based Democrat Marc Veasey. However, Veasey was drawn out of the 33rd district and into the 25th, and ultimately chose to pursue a short-lived bid for Tarrant County judge before abandoning that bid. The new incumbent is Democrat Jasmine Crockett, who was elected with 84.9% of the vote in 2024, in her previous District 30; however, Crockett chose to pursue a run for the United States Senate seat currently held by John Cornyn. Former congressman and 2024 U.S. Senate nominee Colin Allred (who lost in the general election that year to Ted Cruz) and current 32nd District incumbent Julie Johnson ran for the Democratic nomination to represent this district, which is centered in Downtown and Uptown Dallas and also extends in four separate directions - northwest to Love Field and a northern section of Irving centered on the Valley Ranch area, northeast to the Swiss Avenue and Buckner Boulevard (east of White Rock Lake) corridors in east Dallas, southeast to southeast Dallas (including Pleasant Grove) and Balch Springs, and southwest to West Dallas as well as Cockrell Hill and central Grand Prairie. The new district gave 65.2% of the vote to Kamala Harris and 68.7% to Allred in 2024, and is over 50 percent Hispanic.
Sources: en.wikipedia.org
Vampires are mythical creatures that drink blood directly for sustenance, usually with a preference for human blood. Cultures all over the world have myths of this kind; for example the 'Nosferatu' legend, a human who achieves damnation and immortality by drinking the blood of others, originates from Eastern European folklore. Ticks, leeches, female mosquitoes, vampire bats, and an assortment of other natural creatures do consume the blood of other animals, but only bats are associated with vampires. This has no relation to vampire bats, which are New World creatures discovered well after the origins of the European myths.
=== Lethality === The mean lethal dose in rats (i.p.) for ATR is 143 mg/kg and for CATR is 2.9 mg/kg. This lethal dose of ATR takes approximately 150–180 minutes after injection until acute tubular necrosis occurred. This lethal dose varies across species and method of exposure. For example, the mean lethal dose of ATR in rats (s.c.) is 155 mg/kg. Published mean lethal doses of ATR in other species includes 250 mg/kg (s.c.) for rabbit, 200 mg/kg (i.p.) for guinea pig, and 15 mg/kg (i.v.) for dog.
Major issues, however, were not agreed upon in the framework agreement, which contains no accord on Iran's nuclear program or uranium stockpiles, although it does call for the downgrading of Iranian uranium from weapons-grade to reactor-grade following a final agreement. These issues are deferred to future talks to take place over the 60-day ceasefire extension. The framework agreement also does not mention the Iranian ballistic missile program or its network of non-state allies in the Middle East. Within 25 days of signing the memorandum, Iran’s Ministry of Foreign Affairs accused Washington of violating "nearly all parts" of the agreement citing attacks on transport infrastructure and fishing vessels.
== History == Viracor-IBT was created through the merger of two specialty diagnostic testing labs, Viracor Laboratories and IBT Laboratories. Founded by Dr. Konstance Knox and Dr. Donald Carrigan in Milwaukee County in 2000, Viracor was among the first to commercially offer real-time quantitative PCR assays to diagnose patients with Adenovirus, BK virus and JC virus, among others. Founded in 1983, IBT was the first laboratory to offer a test to definitively diagnose autoimmune causes of chronic hives and developed the first commercially available test to measure pneumococcal antibodies. On 1 July 2014, Ampersand Capital Partners completed the sale of Viracor-IBT Laboratories to Eurofins Scientific for $255 million. The company continued to be known as Viracor-IBT.
Sources: en.wikipedia.org
=== Legal status === In February 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hyftor, intended for the treatment of angiofibroma. The applicant for this medicinal product is Plusultra pharma GmbH. Hyftor was authorized for medical use in the European Union in May 2023. Sirolimus, as Rapamune solution, was approved for medical use in the United States in 1999; and as Rapamune tablets in August 2000. Sirolimus, as Fyarro, was approved for medical use in the United States in November 2021. Sirolimus, as Hyftor, was approved for medical use in the United States in March 2022.
=== Tribofilm formation mechanism === Various mechanisms have been proposed for how ZDDP forms protective tribofilms on solid surfaces. In-situ atomic-force microscopy (AFM) experiments show that the growth of ZDDP tribofilms increases exponentially with both the applied pressure and temperature, consistent with a stress-promoted thermal activation reaction rate model. Subsequently, experiments with negligible solid-solid contact demonstrated that film formation rate depends on the applied shear stress.
=== First endosymbiosis === Eukaryotic algae are polyphyletic thus their origin cannot be traced back to a single hypothetical common ancestor. It is thought that they came into existence when photosynthetic coccoid cyanobacteria got phagocytized by a unicellular heterotrophic eukaryote (a protist), giving rise to double-membranous primary plastids. Such symbiogenic events (primary symbiogenesis) are believed to have occurred more than 1.5 billion years ago during the Calymmian period, early in Boring Billion, but it is difficult to track the key events because of so much time gap. Primary symbiogenesis gave rise to three divisions of archaeplastids, namely the Viridiplantae (green algae and later plants), Rhodophyta (red algae) and Glaucophyta ("grey algae"), whose plastids further spread into other protist lineages through eukaryote-eukaryote predation, engulfments and subsequent endosymbioses (secondary and tertiary symbiogenesis). This process of serial cell "capture" and "enslavement" explains the diversity of photosynthetic eukaryotes. The oldest undisputed fossil evidence of eukaryotic algae is Bangiomorpha pubescens, a red alga found in rocks around 1047 million years old.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.